沙利度胺联合美法仑及VAD方案治疗多发性骨髓瘤24例  

The efficacy observation of thalidomide plus melphalan and VAD regimen in the treatment of multiple myeloma

作　　者：章红涛[1] 贺永春[1] 张艳芳[1] 赵芳[1] 张利东[1] 

机构地区：[1]大同市第三人民医院血液内科 ,037008

出　　处：《白血病．淋巴瘤》2009年第4期226-227,共2页Journal of Leukemia & Lymphoma

摘　　要：目的评估沙利度胺联合美法仑及VAD方案治疗多发性骨髓瘤（MM）的疗效及不良反应。方法治疗组共24例患者，均给予沙利度胺联合美法仑及VAD方案化疗，治疗2个疗程观察疗效。观察项目包括血清M蛋白、肝肾功能、尿蛋白、骨髓象、血象等，记录患者不良反应。疗效标准分为完全缓解（CR）、部分缓解（PR）、未缓解（NR）。结果治疗组24例患者中CR13例，PR6例，NR5例，有效率79．17％。结论沙利度胺联合美法仑及VAD方案治疗MM的临床疗效显著，症状改善明显。Objective To evaluate the efficacy and adverse effects of thalidomide plus melphalan and VAD regimen in the treatment of multiple myeloma（MM）. Methods 24 patients in the treatment group were treated with thalidomide plus melphalan and VAD regimen. Two continuous treatment were considered valuable. Observational content included results of serum myeloma protein; liver and renal function; protein- uria of 24-hours; bone marrow and peripheral blood and soon. The side reactions were recorded. The clinical efficacy evaluation was divided into complete response（CR）, partial response（PR）, none response（NR）. Results 13 cases in the treatment group achieved CR, 6 cases achieved PR, 5 cases no change, 19 cases achieved overall response. Conclusion The prominent clinical efficacy was achieved with thalidomide plus melphalan and VAD regimen in multiple myeloma. The clinical manifestation was improved significantly.

关 键 词：多发性骨髓瘤 药物疗法 联合 美法仑 长春新碱 地塞米松 沙利度胺 

分 类 号：R733.3[医药卫生—肿瘤]